Title |
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
|
---|---|
Published in |
Experimental Hematology & Oncology, February 2021
|
DOI | 10.1186/s40164-021-00203-8 |
Pubmed ID | |
Authors |
Patrick B. Johnston, Amanda F. Cashen, Petros G. Nikolinakos, Anne W. Beaven, Stefan Klaus Barta, Gajanan Bhat, Steven J. Hasal, Sven De Vos, Yasuhiro Oki, Changchun Deng, Francine M. Foss |
Abstract |
Belinostat is a histone deacetylase inhibitor approved for relapsed refractory peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the maximum tolerated dose (MTD) of belinostat combined with CHOP (Bel-CHOP). Secondary objectives included safety/tolerability, overall response rate (ORR), and belinostat pharmacokinetics (PK). Patients were ≥ 18 years with histologically confirmed, previously untreated PTCL. Patients received belinostat (1000 mg/m2 once daily) + standard CHOP for 6 cycles with varying schedules using a 3 + 3 design in Part A. Part B enrolled patients at MTD dose. Twenty-three patients were treated. One patient experienced DLT (Grade 3 non-hematologic toxicity) on Day 1-3 schedule, resulting in escalation to Day 1-5 schedule (n = 3). No DLTs were observed and Day 1-5 schedule with 1000 mg/m2 was declared as MTD. Twelve additional patients were enrolled in Part B using MTD. Median relative dose intensity was 98%. All patients experienced adverse events (AEs), including nausea (78%), fatigue (61%), and vomiting (57%). Serious AEs occurred in 43%, with febrile neutropenia (17%) and pyrexia (13%). Overall ORR was 86% with 71% reported CR at MTD. Belinostat PK parameters were similar to single-agent. Bel-CHOP was well tolerated and MTD in CHOP combination was the same dose and schedule as single agent dosing. ClinicalTrials.gov Identifier: NCT01839097. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 28 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 6 | 21% |
Researcher | 3 | 11% |
Student > Bachelor | 2 | 7% |
Student > Postgraduate | 2 | 7% |
Student > Doctoral Student | 1 | 4% |
Other | 4 | 14% |
Unknown | 10 | 36% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 6 | 21% |
Chemistry | 2 | 7% |
Biochemistry, Genetics and Molecular Biology | 2 | 7% |
Mathematics | 1 | 4% |
Business, Management and Accounting | 1 | 4% |
Other | 5 | 18% |
Unknown | 11 | 39% |